… of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence
of circulating tumor DNA (ctDNA) … The benefit of adjuvant chemotherapy for ctDNA-positive …

… detection and growth rate assessment provides unique opportunities for guiding … ctDNA
measurements have previously been reported in the context of stage II–III colorectal cancer (9). …

… How long before the ctDNA-guided adjuvant chemotherapy of stage II CRC can reach …
Two ctDNA tests save nearly half of patients from adjuvant chemotherapy, which is highly …

… as the detection of circulating tumor DNA (ctDNA) carrying tumor-… the most from a systemic
adjuvant treatment. Based on that … -operative ctDNA detection in stage II colon cancer patients. …

… Recent technological advances in circulating tumour DNA (ctDNA… with stage II colon cancer
requiring adjuvant chemotherapy … and help guide adjuvant chemotherapy decision in stage II …

… of adjuvant chemotherapy in patients with colorectal cancer. Nat … of ctDNA-guided
management of stage II colon cancer as … ctDNA assays following surgery received less adjuvant …

… ctDNA testing to guide adjuvant chemotherapy decision making for patients with stage II colon
cancer. … ctDNA results would influence treatment recommendations in most patients, with …

… implementation of ctDNA-based testing in guiding adjuvant therapy decisions and … stage
II colon cancer), randomization between standard therapy and ctDNA-guided adjuvant therapy …

… a ctDNA-guided approach versus standard management in stage II colon cancer (CC) reduced
adjuvant chemotherapy (… MMR status defines two distinct subsets of stage II CC. Here, we …

… of care, using circulating tumour DNA to guide adjuvant chemotherapy reduced adjuvant
chemotherapy … Circulating tumour DNA was found to be a potentially cost-effective biomarker in …